|
Valacyclovir in Immunocompromised Children Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Valacyclovir in Immunocompromised Children conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Valacyclovir in Immunocompromised Children Clinical research trials and Valacyclovir in Immunocompromised Children medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Valacyclovir in Immunocompromised Children. Valacyclovir in Immunocompromised Children Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Valacyclovir in Immunocompromised Children clinical trial. Participants frequently obtain the most expert healthcare available for their Valacyclovir in Immunocompromised Children condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Valacyclovir in Immunocompromised Children  Valacyclovir in Immunocompromised Children
Valacyclovir in Immunocompromised Children
For Condition: Shingles,Bone Marrow Transplantation
Status: Recruiting
Sponsor(s): Baylor College of Medicine , Texas Children's Hospital
Synopsis: Shingles is an infection commonly seen in children with a weakened immune system (immunocompromised children). The immune system can be weakened as a result of medications that patients receive for cancer or other serious illness or as a result of a bone marrow transplantation. Shingles in children with a weakened immune system may spread throughout the body and in some instances may be life-threatening. Acyclovir is a medication that is routinely used to treat immunocompromised children with shingles in order to prevent further spread of their shingles and to help them heal faster. Acyclovir is also given to bone marrow transplant patients to prevent reactivation of HSV infection. Valacyclovir is a new drug that is metabolized (broken down in the body) to acyclovir. Valacyclovir is given by mouth and studies done in adults have shown it to be more effective than acyclovir given by mouth. The purpose of this study is to - study the pharmacology of this drug (how the body handles this drug), - determine if oral Valacyclovir can be safely given to children with shingles, and - determine the type of side effects that occur when oral Valacyclovir is given to immunocompromised children.
Details: Patients with shingles: Patients with shingles will receive oral Valacyclovir three times a day for 5 to 10 days. For the first 24 hours of treatment, patients will be admitted to the hospital for close monitoring. If there are no problems after the first 24 hours then the patient may be discharged to take the medicine at home. After discharge patinets will be seen and examined in clinic daily for the first 5 days, then on day 7 and after that every other day until the shingles show evidence of healing. A final physical exam and blood tests occur on day 21. A small amount of fluid will be taken from one of the shingles lesions using a very fine needle to verify the presence of the virus that causes shingles. This will be done before the first dose of Valacyclovir and 3 days later. Blood tests (no more than 2 teaspoons) will be performed twice a week to monitor for toxic effects of the drug. Blood samples will be drawn to evaluate the pharmacology of this drug(how the body handles the drug). Nine blood samples (less than one teaspoon each) will be obtained over 24 hours during the first day of treatment. The total amount of blood to be drawn is 9 teaspoons (3 tablespoons). For children that are toilet trained, urine will be collected for 12 hours at the start of the study. This urine will be used to evaluate kidney function, and the pharmacology of valacyclovir. If there are unacceptable side effects or if there is evidence that the disease is spreading, despite being on Valacyclovir for more than 48 hours, then you will be taken off the study and started on acyclovir by vein. Patients Undergoing Bone Marrow Transplantation: Patients undergoing a bone marrow transplant will receive a single dose of valacyclovir in place of thier first scheduled dose of acyclovir. They will then receive acyclovir as outlined by their physician. Blood samples will be drawn to evaluate the pharmacology (how the body handles the drug) of the study drug. Fifteen blood samples (less than one teaspoon each) will be obtained over 24 hours during the first day of treatment. The total amount of blood to be drawn is 9 teaspoons (3 tablespoons. The total amount of blood drawn for all blood work including routine blood tests as well as pharmacokinetics will not be greater than 5% of the patients total blood volume. This amount of blood loss is a safe amount even for small children
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 2 Years/18 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients must be >/= 2 and 8 weeks. - Patients must be receiving chemotherapy or have been treated with bone marrow transplantation or chemotherapy for an underlying malignancy or medical condition in the past 12 months, or have an underlying immunodefiency syndrome. - Patients must have adequate hepatic function (bilirubin 1.5 mg/dl: SGPT < 3x normal) and adequate renal function (creatinine 1.2 mg/dl or creatinine clearance 60 ml/min/1.73 m2). - Acute Zoster Infection: Patients must have acute herpes zoster defined as 3 days. - Patients in relapse, (Stratum I only), or unstable medical conditions due to underlying disease. - Patients with suspected acyclovir-resistant VZV infection. - Patients who received systemic antiherpetic therapy in the previous 2 weeks before the onset of VZV infection. - Patients with known history of adverse reaction to acyclovir in the past.
Total Enrollment: 30
Location and Contact Information:
Texas Children's Hospital *Recruiting*
Houston, Texas, 77030
United States
Recruiting Susan Blaney 832-822-4215
Children's Hospital of Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19104
United States
Recruiting Donna Sylvester 215-590-3284
Additional Information:
Study ID Numbers: H6644; Valacyclovir
Study Start Date: May 1998
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00059592
Other Shingles Studies:
1. The Effects of Music Therapy-Based Stress Reduction on Bone Marrow Transplant Recipients
2. Retention of Bone Marrow Donors in a National Registry
3. Sibling Donor Cord Blood Banking and Transplantation
4. Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients who have had Donor Marrow Grafts.
5. National Marrow Donor Program (NMDP)
Related Studies:
Other Shingles Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
Valacyclovir in Immunocompromised Children
|
|
|
|
|
|
|
|
